Presse & Publications

Nous rencontrer

26e congrès annuel de la Société internationale des troubles bipolaires (ISBD)

du 29 septembre au 1er octobre 2024 à Reykjavik, Islande

Venez nous rencontrer au congrès de l’ISBD 2024 ! Notre directrice scientifique, Dr. Dinah Weissmann, donnera une conférence intitulée : « 𝗔𝗜 𝗔𝗹𝗴𝗼𝗿𝗶𝘁𝗵𝗺 𝗖𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝗪𝗶𝘁𝗵 𝗥𝗡𝗔 𝗘𝗱𝗶𝘁𝗶𝗻𝗴-𝗕𝗮𝘀𝗲𝗱 𝗕𝗹𝗼𝗼𝗱 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 𝘁𝗼 𝗗𝗶𝘀𝗰𝗿𝗶𝗺𝗶𝗻𝗮𝘁𝗲 𝗕𝗶𝗽𝗼𝗹𝗮𝗿 𝗙𝗿𝗼𝗺 𝗠𝗮𝗷𝗼𝗿 𝗗𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗗𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 », le dimanche 29 septembre, à partir de 17 : 30 GMT (session orale New & Trending Oral Session II)

Presse

https://www.alcediag-alcen.com/wp-content/uploads/2024/04/grand-prix-check-up-sante-scaled.jpg
Award | avril 26, 2024

Winner of the Medical Biology Award – Grands Prix Check Up Santé 2024

https://www.alcediag-alcen.com/wp-content/uploads/2024/03/Test-myEDIT-B-differencier-la-depression-et-les-troubles-bipolaires-arrive-France.png
Press Release | mars 22, 2024

SYNLAB et ALCEDIAG lancent en France le test sanguin myEDIT-B pour différencier la dépression et les troubles bipolaires.

https://www.alcediag-alcen.com/wp-content/uploads/2023/11/Edit-B-Kit-Box.jpg
Press Release | novembre 06, 2023

50% Recruitment milestone reached in clinical validation study of EDIT B blood test: An aid for differential diagnosis of bipolar disorder based on RNA Editing biomarkers

https://www.alcediag-alcen.com/wp-content/uploads/2023/10/ALCEDIAG-laureat.jpeg
Award | octobre 09, 2023

Finalist list of the European Lifestars Awards – Celebrating Life Science eXecutives & their partners!

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/PHOTO-2023-04-04-14-26-47.jpg
Award | mars 28, 2023

We won the Medical Diagnostic trophy at the 2nd edition of the « Healthtech awards » organised by France Biotech!

https://www.alcediag-alcen.com/wp-content/uploads/2023/03/SynLab-logo.svg
Press Release | mars 27, 2023

ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/Ouest-France-image.jpeg
News | novembre 18, 2022

OUEST-FRANCE À Montpellier, une start-up développe un test pour diagnostiquer la bipolarité

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/ALCEDIAG-1.png
News | juillet 12, 2022

ALCEDIAG Announces the Inclusion of the First Patient in clinical validation study for EDIT-B test: an aid for differential diagnosis of bipolar disorder, based on RNA editing blood biomarkers

Publications scientifiques

International Journal of Molecular Sciences | décembre 03, 2024

RNA Editing Signatures Powered by Artificial Intelligence: A New Frontier in Differentiating Schizophrenia, Bipolar, and Schizoaffective Disorders

Francisco J. Checa-Robles, Nicolas Salvetat, Christopher Cayzac, Mary Menhem, Mathieu Favier, Diana Vetter, Ilhème Ouna, João V. Nani, Mirian A. F. Hayashi, Elisa Brietzke, Dinah Weissmann

Journal of Affective Disorder | avril 22, 2024

AI algorithm combined with RNA editing-based blood biomarkers to discriminate bipolar from major depressive disorders in an external validation multicentric cohort

Nicolas Salvetat, Francisco Jesus Checa-Robles, Aurélie Delacrétaz, Christopher Cayzac, Benjamin Dubuc, Diana Vetter, Jacques Dainat, Jean-Philippe Lang, Franziska Gamma, Dinah Weissmann

Psychiatry Research | septembre 10, 2023

Euthymic and depressed bipolar patients are characterized by different RNA editing patterns in blood

Mirian A.F. Hayashi, Nicolas Salvetat, Christopher Cayzac, Francisco Jesus Checa-Robles, Benjamin Dubuc, Sandie Mereuze, João V. Nani, Franck Molina, Elisa Brietzke, Dinah Weissmann

Translational Psychiatry | juillet 06, 2022

A game changer for bipolar disorder diagnosis using RNA editing-based biomarkers

Nicolas Salvetat, Francisco Jesus Checa-Robles, Vipul Patel, Christopher Cayzac, Benjamin Dubuc, Fabrice Chimienti, Jean-Daniel Abraham, Pierrick Dupré, Diana Vetter, Sandie Méreuze, Jean-Philippe Lang, David J. Kupfer, Philippe Courtet, Dinah Weissmann

Translational Psychiatry | mars 05, 2021

Phosphodiesterase 8A to discriminate in blood samples depressed patients and suicide attempters from healthy controls based on A-to-I RNA editing modifications

Nicolas Salvetat, Fabrice Chimienti, Christopher Cayzac, Benjamin Dubuc, Francisco Checa-Robles, Pierrick Dupre, Sandie Mereuze, Vipul Patel, Catherine Genty, Jean-Philippe Lang, Jean-François Pujol, Philippe Courtet & Dinah Weissmann

Journal of NeuroVirology | octobre 21, 2019

RNA editing blood biomarkers for predicting mood alterations in HCV patients

N. Salvetat, S. Van der Laan, B. Vire, F. Chimienti, S. Cleophax, J. P. Bronowicki, M. Doffoel, M. Bourlière, R. Schwan, J. P. Lang, J. F. Pujol, D. Weissmann

Translational Psychiatry | février 15, 2019

Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents

Fabrice Chimienti, Laurent Cavarec, Laurent Vincent, Nicolas Salvetat, Victoria Arango, Mark D. Underwood, J. John Mann, Jean-François Pujol, Dinah Weissmann

Drug Discovery Today | avril 14, 2017

Emerging RNA editing biomarkers will foster drug development

S. Van der Laan, S. Salvetat, D. Weissmann, F. Molina

Translational Psychiatry | août 30, 2016

Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression

D Weissmann, S van der Laan, MD Underwood, N Salvetat, L Cavarec, L Vincent, F Molina, JJ Mann, V Arango and JF Pujol

Translational Psychiatry | août 20, 2016

In vitro screening for drug-induced depression and/or suicidal adverse effects: a new toxicogenomic assay based on CE-SSCP analysis of HTR2C mRNA editing in SH-SY5Y cells

D Weissmann, S van der Laan, MD Underwood, N Salvetat, L Cavarec, L Vincent, F Molina, JJ Mann, V Arango and JF Pujol